Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology
BOSTON -- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that three abstracts have been accepted for presentation at the 73rd annual meeting of the American Academy of Neurology (AAN), taking place virtually from April 17 through April 22, 2021. New real-world data will be presented evaluating SOLIRIS® (eculizumab) for the treatment of generalized myasthenia gravis (gMG) in the United States, suggesting substantial reductions in myasthenic crises, exacerbations and related hospitalizations, consistent with results from the Phase 3 REGAIN clinical trial and the open-label extension. Additionally, long-term data on SOLIRIS for the treatment of neuromyelitis optica spectrum disorder (NMOSD) will be presented, including a disease model assessing the benefits of treatment and Phase 3 PREVENT clinical trial results evaluating SOLIRIS as a monotherapy.
The accepted abstracts are listed below and are now available on the AAN website. Posters will be available throughout the duration of the Congress.
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Long-Term Efficacy and Safety of Eculizumab Monotherapy in AQP4+ Neuromyelitis Optica Spectrum Disorder. Oral presentation, Program Number S29.004, Session S29: Autoimmune Neurology: Clinical Trials, Treatment, and Diagnosis of CNS and PNS Autoimmune Neurologic Disorders, April 21, 2021, 4:00 p.m. – 5:00 p.m. Eastern Time.
The Potential Impact of Long-Term Relapse Reduction: A Disease Model of Eculizumab in Neuromyelitis Optica Spectrum Disorder. ePoster presentation, Program Number P15.055, Session P15: MS Clinical Practice and Decision Making.
Generalized Myasthenia Gravis (gMG)
Real-World Use of Eculizumab in Generalized Myasthenia Gravis in the United States: Results from a Pilot Retrospective Chart-Review Study. ePoster presentation, Program Number P2.062, Session P2: Autoimmune Neurology: Inflammatory Neuropathies and Stiff Person Syndrome.
About Neuromyelitis Optica Spectrum Disorder (NMOSD)
Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare autoimmune disease of the central nervous system (CNS). Approximately three-quarters of NMOSD patients have anti-AQP4 antibody-positive NMOSD. In patients with these antibodies, NMOSD occurs when the complement system—a part of the body’s immune system—over-responds—leading the body to primarily attack the optic nerves and/or spinal cord in the CNS. People living with NMOSD often experience unpredictable attacks, also referred to as relapses, which tend to be severe and recurrent and may result in permanent disability. The most common symptoms of NMOSD are optic neuritis, which can cause visual problems including blindness, and transverse myelitis, which can cause mobility problems including paralysis. The disease primarily affects women, with an average age of onset of 39 years. NMOSD is more common and more severe in non-Caucasian populations worldwide.
About Generalized Myasthenia Gravis (gMG)
Myasthenia gravis (MG) is a rare, progressive, autoimmune neuromuscular disease. In patients with anti-acetylcholine receptor (AchR) antibody-positive MG, the body’s own immune system over-responds, leading the body to attack its own healthy cells and produce antibodies to fight against AchR, a receptor located on muscle cells at the neuromuscular junction. As a result, communication between the nerves and muscles is impaired, leading to a loss of normal muscle function. MG typically begins with weakness in the muscles that control the movements of the eyes and eyelids and often progresses to the more severe and generalized form, known as generalized myasthenia gravis (gMG). People with gMG can suffer from slurred speech, choking, difficulty swallowing, drooping of the eyelids, double or blurred vision, disabling fatigue, immobility requiring assistance, shortness of breath and episodes of respiratory failure that can be life-threatening. Complications, exacerbations and myasthenic crises can require hospital and intensive care unit admissions with prolonged stays. gMG can occur at any age but most commonly begins before the age of 40 in women and after the age of 60 in men.